Attached files

file filename
EX-31.1 - EXHIBIT 31.1 - PLURISTEM THERAPEUTICS INCexhibit_31-1.htm
EX-32.2 - EXHIBIT 32.2 - PLURISTEM THERAPEUTICS INCexhibit_32-2.htm
EX-31.2 - EXHIBIT 31.2 - PLURISTEM THERAPEUTICS INCexhibit_31-2.htm
EX-10.2 - EXHIBIT 10.2 - PLURISTEM THERAPEUTICS INCexhibit_10-2.htm
EX-10.1 - EXHIBIT 10.1 - PLURISTEM THERAPEUTICS INCexhibit_10-1.htm
10-Q - 10-Q - PLURISTEM THERAPEUTICS INCzk1719457.htm

Exhibit 32.1
18 U.S.C. SECTION 1350
In connection with the Quarterly Report (the "Report") of Pluristem Therapeutics Inc. (the "Company") on Form 10-Q for the period ended December 31, 2016, as filed with the Securities and Exchange Commission on the date hereof, I, Zami Aberman, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date:  February 8, 2017

By: /s/ Zami Aberman
Zami Aberman
Chief Executive Officer